Event Highlights - May 5, 2026
Highlights from Vitalis
As the largest Nordic event for digital health, health tech, person-centered care, Vitalis 2026 did indeed bring together the full life science and healthcare ecosystems.
CDMO - May 5, 2026
Diamyd Medical advances manufacturing of biologics
The company has established manufacturing capacity in accordance with current quality requirements and regulatory guidelines, it states.
Financing - May 5, 2026
IRLAB resolves on a rights issue of approx SEK 68 million
The Board of Directors of IRLAB Therapeutics has resolved on a rights issue of shares of series A corresponding to approximately SEK 68 million.
Careers article - May 5, 2026
BioNTech to exit manufacturing sites – affecting 1,860 positions
BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech’s partners’ manufacturing capacities and completion of contracts, it states. The company plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac’s sites, affecting up […]
Acquisition - May 5, 2026
Chiesi Group to acquire KalVista Pharmaceuticals
Under the terms of the Transaction, Chiesi will commence a tender offer to acquire all outstanding shares of KalVista for USD 27.00 per share in cash. The total value implied by the transaction at closing is approximately USD 1.9 billion.
Acquisition - May 4, 2026
UCB to acquire Candid Therapeutics
Belgian company UCB has announced signing of a definitive agreement under which it would acquire Candid Therapeutics, a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs).
